Phase2 Study of TS-141 in Child Patients With ADHD (Double-blind, Parallel Group Study)
Latest Information Update: 25 Mar 2022
Price :
$35 *
At a glance
- Drugs Tipepidine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 05 Feb 2018 Status changed from recruiting to completed.
- 15 Jun 2016 New trial record